Multicentre clinical evaluation of the COBAS CORE CEA, CA 125 II and PSA tumor marker assays.
The aim of our study was to evaluate the clinical usefulness of the tumor markers CEA, CA 125 and PSA using the COBAS CORE system from Roche Diagnostic Systems. Our results demonstrate that determination of these markers on the COBAS CORE immunoassay analyser provides the performance required for routine use in clinical practice. The results obtained in this clinical trial validate the correlation with disease extension, a characteristic that defines and determines the clinical utility of the tumor markers. We also conclude that learning to operate the COBAS CORE system is simple, as is management of the system through the user-friendly software.
Filella
X
X
Department of Clinical Biochemistry (Unit for Cancer Research), Hospital Clinic Provincial, Barcelona, Spain.
Ballesta
A M
AM
Fox
M
M
Mitchell
H
H
Molina
R
R
Pürstner
P
P
Thome
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018394:CA-125 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000295:instrumentation / Q000379:methods; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D012016:Reference Values; D015203:Reproducibility of Results; D012907:Smoking
D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D017430:Prostate-Specific Antigen